<b>Conclusions:</b> These results demonstrate that Compound <b>#765</b> functions as a LOXL2 inhibitor with significant anti-fibrotic effects in vitro and in vivo, offering a promising therapeutic approach for IPF and other fibrotic lung diseases. This evidence concerns the gene LOXL2 and idiopathic pulmonary fibrosis.